Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 10.86% is 109% above its 5-year average of 5.19%, near the high end of its 5-year range (0.00%–10.86%).
As of the fiscal period ended Sunday, May 31, 2026. 13.65% above its 12-month average of 9.55%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-05-31): 10.86%.
DEBT TO ASSETS RATIO
10.86%
DEBT TO ASSETS RATIO AVG TTM
9.55%
DEBT TO ASSETS RATIO AVG 3Y
6.96%
DEBT TO ASSETS RATIO AVG 5Y
5.19%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+13.65%
CURRENT VS 3Y AVG
+56.05%
CURRENT VS 5Y AVG
+109.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 873 covered companies
CURRENT VS SECTOR MEDIAN
+11963.21%
vs the sector median at left
Nurix Therapeutics, Inc.
Market Cap
$2.35B
Debt to Assets Ratio
10.86%
TTM Avg
9.55%
3Y Avg
6.96%
5Y Avg
5.19%
Market Cap
$2.34B
Debt to Assets Ratio
0.20%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.36B
Debt to Assets Ratio
0.30%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.38B
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.30B
Debt to Assets Ratio
0.25%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.28B
Debt to Assets Ratio
0.11%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.43B
Debt to Assets Ratio
0.05%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.24B
Debt to Assets Ratio
0.13%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nurix Therapeutics, Inc. (NRIX) | $2.35B | 10.86% | 9.55% | 6.96% | 5.19% |
| UFP Technologies, Inc. (UFPT)vs › | $2.34B | 0.20% | N/A | N/A | N/A |
| ADMA Biologics, Inc. (ADMA)vs › | $2.36B | 0.30% | N/A | N/A | N/A |
| Disc Medicine, Inc. (IRON)vs › | $2.37B | 0.08% | N/A | N/A | N/A |
| Clover Health Investments, Corp. (CLOV)vs › | $2.38B | 0.00% | N/A | N/A | N/A |
| Liquidia Corporation (LQDA)vs › | $2.30B | 0.25% | N/A | N/A | N/A |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.28B | 0.11% | N/A | N/A | N/A |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.43B | 0.05% | N/A | N/A | N/A |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.24B | 0.13% | N/A | N/A | N/A |
| Supernus Pharmaceuticals, Inc. (SUPN)vs › | $2.49B | 0.03% | N/A | N/A | N/A |
Debt/Assets
10.9%
Debt/Equity
0.14
Current Ratio
6.34
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-05-31 | 10.86% |
| 2026-02-28 | 9.22% |
| 2025-11-30 | 8.10% |
| 2025-08-31 | 10.81% |
| 2025-05-31 | 8.78% |
| 2025-02-28 | 4.33% |
| 2024-11-30 | 4.23% |
| 2024-08-31 | 5.28% |
| 2024-05-31 | 5.64% |
| 2024-02-29 | 9.32% |
| 2023-11-30 | 8.61% |
| 2023-08-31 | 2.60% |
| 2023-05-31 | 2.66% |
| 2023-02-28 | 2.88% |
| 2022-11-30 | 2.87% |
| 2022-08-31 | 2.88% |
| 2022-05-31 | 3.68% |
| 2022-02-28 | 3.60% |
| 2021-11-30 | 2.73% |
| 2021-08-31 | 0.00% |
| 2021-05-31 | 0.00% |
| 2021-02-28 | 0.00% |
| 2020-11-30 | 0.00% |
| 2020-08-31 | 0.00% |
| 2020-05-31 | 0.00% |
| 2020-02-29 | 54.28% |
| 2019-11-30 | 0.00% |
